Amicus Therapeutics, Inc.
(NASDAQ : FOLD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.45%166.930.7%$1253.55m
LLYEli Lilly & Co. 0.18%311.431.1%$814.08m
BMYBristol-Myers Squibb Co. -0.73%70.771.0%$778.85m
PFEPfizer Inc. -1.10%44.080.9%$769.71m
ABBVAbbVie, Inc. 0.04%143.061.9%$735.85m
MRKMerck & Co., Inc. -0.81%86.800.7%$691.58m
AZNAstraZeneca Plc -3.07%54.581.0%$397.16m
ALNYAlnylam Pharmaceuticals, Inc. -0.95%200.788.2%$207.03m
NVSNovartis AG -1.47%76.010.2%$201.13m
GBTGlobal Blood Therapeutics, Inc. 0.03%67.995.4%$199.71m
GSKGSK Plc -2.13%29.370.3%$192.16m
NVONovo Nordisk A/S -0.40%97.920.1%$170.11m
HZNPHorizon Therapeutics Plc 0.54%62.975.4%$156.21m
SGENSeagen Inc. -0.96%139.205.7%$152.48m
SRPTSarepta Therapeutics, Inc. -2.42%108.1912.4%$128.76m

Company Profile

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.